Skip to main content
. 2017 Feb 20;3(2):e00251. doi: 10.1016/j.heliyon.2017.e00251

Table 2.

Group cohorts’ comparison.

Controls Supplemented P
Gender
Male 8/8 (100.0%) 15/18 (83.3%) 0.529
Female 0/8 (0.0%) 3/18 (16.7%)
Age (years ± SD) 62.0 ± 6.2 65.8 ± 10.1 0.337
Chemotherapy cycles 3.0 ± 1.6 3.6 ± 1.5 0.365
Cisplatin dose (mg) 456.8 ± 195.5 464.6 ± 110.7 0.897
Metastases 2/8 (25.0%) 2/18 (11.1%) 0.563
Concomitant radiotherapy 6/8 (75.0%) 12/18 (66.7%) 1.000
Previous otologic pathologies 1/8 (12.5%) 3/18 (16.7%) 1.000
Previous tinnitus 1/8 (12.5%) 2/18 (11.1%) 1.000